ArticleImmunity2021
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants.
Open access · bronzeAbstract read
In one paragraph
Article in Immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.Nature communications · 2022Trial
- Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunization.Science immunology · 2025Article
- Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants.Biosensors & bioelectronics · 2025Article
- Clonotype-enriched somatic hypermutations drive affinity maturation of a public human antibody targeting an occluded sarbecovirus epitope.Cell reports · 2025Article
- Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.Journal of virology · 2025Article
- Review
- Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoprotein.bioRxiv : the preprint server for biology · 2024Article
- Differential immunometabolic responses to Delta and Omicron SARS-CoV-2 variants in golden syrian hamsters.iScience · 2024Article
- A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies.JCI insight · 2024Article
- COVID-19 Crisis in Brazil: Post-Vaccination Seroprevalence and Infection in More and Less Vaccinated Municipalities in a Northeastern State.Life (Basel, Switzerland) · 2024Article
- Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis.Frontiers in immunology · 2024Article
- Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes.Cell reports · 2023Article
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants.The Journal of clinical investigation · 2023Article
- State of the art in epitope mapping and opportunities in COVID-19.Future science OA · 2023Review
- Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations.Pathogens (Basel, Switzerland) · 2022Review
- A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.Emerging microbes & infections · 2022Article
- Vaccines against SARS-CoV-2 variants and future pandemics.Expert review of vaccines · 2022Review
- SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.bioRxiv : the preprint server for biology · 2022Article
- Protective neutralizing epitopes in SARS-CoV-2.Immunological reviews · 2022Review
Corrections and comments
- Update of
Authors and funding
29 authors at 4 institutions in 1 country.
Aaron J SchmitzDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Jackson S TurnerDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Zhuoming LiuDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Julian Q ZhouDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Ishmael D AziatiDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Rita E ChenDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Astha JoshiDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Traci L BrickerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Tamarand L DarlingDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Daniel C AdelsbergDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clara G AltomareDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wafaa B AlsoussiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Laura A VanBlarganDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Tingting LeiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Mahima ThapaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Fatima AmanatDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Trushar JeevanDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Thomas FabrizioDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jane A O'HalloranDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Rachel M PrestiDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO, USA.
Richard J WebbyDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sean P J WhelanDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Goran BajicDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Michael S DiamondDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA.
Adrianus C M BoonDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: jboon@wustl.edu.
Ali H EllebedyDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: ellebedy@wustl.edu.
Washington University in St. Louis · USIcahn School of Medicine at Mount Sinai · USSt. Jude Children's Research Hospital · USThe University of Texas Medical Branch at Galveston · US
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4MNCCAT: National Center for CryoEM Access and Training- Supplement for Windows 10 and FFIU24GM129539 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · PI DE MARCO, ALEX, KIEFT, JEFFREY S · 2018 to 2023
$53.9MUTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0MTRAINING IN THE IMMUNOBIOLOGY AND MOLECULAR CELL BIOLOGY OF CANCERT32CA009547 · NCI · WASHINGTON UNIVERSITY · PI ROBERT DAVID SCHREIBER · 1986 to 2026
$12.1MCOVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.75N93019C00062 · NIAID · WASHINGTON UNIVERSITY · PI FREMONT, DAVED · 2019 to 2023
$11.7MEmerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MDYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9MProgramming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3MRegulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1MNCATS NIH HHS UL1 TR001439NCATS NIH HHS UL1 TR002345NCI NIH HHS T32 CA009547NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00062NIAID NIH HHS 75N93021C00016NIAID NIH HHS HHSN272201400006CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI118938NIAID NIH HHS R01 AI134907NIAID NIH HHS R01 AI157155NIAID NIH HHS U01 AI141990NIAID NIH HHS U01 AI150747NIAID NIH HHS U01 AI151810NIGMS NIH HHS U24 GM129539
Abstract
The emergence of SARS-CoV-2 antigenic variants with increased transmissibility is a public health threat. Some variants show substantial resistance to neutralization by SARS-CoV-2 infection- or vaccination-induced antibodies. Here, we analyzed receptor binding domain-binding monoclonal antibodies derived from SARS-CoV-2 mRNA vaccine-elicited germinal center B cells for neutralizing activity against the WA1/2020 D614G SARS-CoV-2 strain and variants of concern. Of five monoclonal antibodies that potently neutralized the WA1/2020 D614G strain, all retained neutralizing capacity against the B.1.617.2 variant, four also neutralized the B.1.1.7 variant, and only one, 2C08, also neutralized the B.1.351 and B.1.1.28 variants. 2C08 reduced lung viral load and morbidity in hamsters challenged with the WA1/2020 D614G, B.1.351, or B.1.617.2 strains. Clonal analysis identified 2C08-like public clonotypes among B cells responding to SARS-CoV-2 infection or vaccination in 41 out of 181 individuals. Thus, 2C08-like antibodies can be induced by SARS-CoV-2 vaccines and mitigate resistance by circulating variants of concern.
Indexed as
AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCells, CulturedClone CellsCOVID-19COVID-19 VaccinesCricetinaeDisease Models, AnimalGerminal CenterHumansLungNeutralization TestsSARS-CoV-2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2B cellgerminal centerhamsterlymph nodemRNA vaccineneutralizing antibodiespublic clonereceptor binding domainSARS-CoV-2spike protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.